Ostar Pharmaceutical

Ostar Pharmaceutical is a clinical-stage biopharmaceutical company dedicated to developing novel small molecule therapeutics for liver and metabolic diseases. The company's primary focus is on the farnesoid X receptor (FXR) pathway, which plays a critical role in bile acid metabolism, lipid regulation, and inflammation. Its lead candidate, OST-1225, is a highly selective, non-bile acid FXR agonist currently being evaluated in Phase 2 clinical trials for indications such as non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). Ostar maintains a dual presence in China and the United States to facilitate global clinical development and regulatory engagement. The company aims to address significant unmet medical needs in chronic liver conditions through its expertise in metabolic signaling.